Fig. 2
From: IL-17A promotes the progression of Alzheimer’s disease in APP/PS1 mice
IL-17Ab ameliorated the decrease in spatial and working memory in APP/PS1 mice. A Schematic of IL-17A or IL-17Ab administration to APP/PS1 mice via intraperitoneal injection. B Escape latency of APP/PS1 mice injected with IL-17A or IL-17Ab during the training phase of the MWM test. n = 5 for each group. C Aβ1-40 levels in the brain tissues of APP/PS1 mice after the injection of IL-17A or IL-17Ab. D Aβ1-42 levels in the brain tissues of APP/PS1 mice after the injection of IL-17A or IL-17Ab. E Representative immunofluorescence images of Aβ plaques in APP/PS1 mice after the injection of IL-17A or IL-17Ab. The values are expressed as the mean ± standard deviation (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05). The data are representative of at least three independent experiments